FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385464226> ?p ?o ?g. }

• W4385464226 endingPage "101397" @default.
• W4385464226 startingPage "101397" @default.
• W4385464226 abstract "We hypothesized that local improvements in bone mineral density (BMD) would be observed following 6 and 18 mo of abaloparatide versus placebo in hip regions corresponding to femoral Gruen zones that influence the fixation and stability of femoral stems in hip arthroplasty. Low BMD at the time of total hip arthroplasty (THA) increases the risk of compromised implant stability and delayed osseointegration (1). Abaloparatide, a synthetic analog to PTHrP(1-34), is FDA approved for the treatment of men and postmenopausal women with osteoporosis. Abaloparatide increases spine and hip BMD and reduces the risk of vertebral and nonvertebral fractures (2). A subset of 500 postmenopausal women with osteoporosis from the ACTIVE trial (2) who received abaloparatide or placebo (n=250/group) were randomly selected. Hip DXA scans obtained after 6 and 18 mo of treatment underwent 3D modeling via 3D-Shaper software (3), and a virtual Stryker (Mahwah, NJ) Accolade II hip stem was optimally sized and positioned within each 3D-DXA scan. Periprosthetic regions corresponding to Gruen zones 1, 2, 6, and 7 were assessed for volumetric BMD (vBMD) (integral, cortical, trabecular) and cortical thickness (zones 3, 4, and 5 were beyond the DXA region of interest). Treatment comparisons were made with P values derived from a mixed-effect model for repeated measures. Abaloparatide significantly increased integral vBMD compared with placebo in Gruen zones 1, 2, 6, and 7 at 6 and 18 mo (P< 0.01 for all) (Table 1). The largest percent increases were in zones 1 and 7. Abaloparatide increased cortical vBMD at 18 mo in all 4 analyzed zones (P< 0.01), increased trabecular vBMD at 6 and 18 mo in zones 1 and 7 (P< 0.0001), and increased cortical thickness at 6 months in zones 1, 6, and 7 (P< 0.01) and in all zones at 18 months (P< 0.001). Color maps of cross-sectional group mean change in vBMD demonstrates more robust BMD accrual with abaloparatide (Figure 1). Abaloparatide significantly increased vBMD and cortical thickness in virtual Gruen zones 1, 2, 6, and 7 compared with placebo. Abaloparatide may represent an effective agent for bone health optimization prior to THA by inducing orthopedically important localized gains in BMD. Additional research into preoperative augmentation and postoperative treatment is warranted. References: 1. Aro HT et al. Acta Orthop 2012;83;107-14; 2. Miller PD et al. JAMA 2017;317:442; 3. Winzenrieth R et al. Osteoporos Int 2021;32:575–83." @default.
• W4385464226 created "2023-08-02" @default.
• W4385464226 creator A5020420660 @default.
• W4385464226 creator A5030297788 @default.
• W4385464226 creator A5037559298 @default.
• W4385464226 creator A5056376224 @default.
• W4385464226 creator A5063920110 @default.
• W4385464226 creator A5085464896 @default.
• W4385464226 creator A5088800404 @default.
• W4385464226 date "2023-07-01" @default.
• W4385464226 modified "2023-09-23" @default.
• W4385464226 title "Abaloparatide Increases Bone Mineral Density in Regions Corresponding to Gruen Zones 1, 2, 6, and 7 in Postmenopausal Women With Osteoporosis" @default.
• W4385464226 doi "https://doi.org/10.1016/j.jocd.2023.101397" @default.
• W4385464226 hasPublicationYear "2023" @default.
• W4385464226 type Work @default.
• W4385464226 citedByCount "0" @default.
• W4385464226 crossrefType "journal-article" @default.
• W4385464226 hasAuthorship W4385464226A5020420660 @default.
• W4385464226 hasAuthorship W4385464226A5030297788 @default.
• W4385464226 hasAuthorship W4385464226A5037559298 @default.
• W4385464226 hasAuthorship W4385464226A5056376224 @default.
• W4385464226 hasAuthorship W4385464226A5063920110 @default.
• W4385464226 hasAuthorship W4385464226A5085464896 @default.
• W4385464226 hasAuthorship W4385464226A5088800404 @default.
• W4385464226 hasConcept C126322002 @default.
• W4385464226 hasConcept C126894567 @default.
• W4385464226 hasConcept C141071460 @default.
• W4385464226 hasConcept C142724271 @default.
• W4385464226 hasConcept C204787440 @default.
• W4385464226 hasConcept C27081682 @default.
• W4385464226 hasConcept C2776541429 @default.
• W4385464226 hasConcept C2776886416 @default.
• W4385464226 hasConcept C2778120723 @default.
• W4385464226 hasConcept C2778336525 @default.
• W4385464226 hasConcept C71924100 @default.
• W4385464226 hasConceptScore W4385464226C126322002 @default.
• W4385464226 hasConceptScore W4385464226C126894567 @default.
• W4385464226 hasConceptScore W4385464226C141071460 @default.
• W4385464226 hasConceptScore W4385464226C142724271 @default.
• W4385464226 hasConceptScore W4385464226C204787440 @default.
• W4385464226 hasConceptScore W4385464226C27081682 @default.
• W4385464226 hasConceptScore W4385464226C2776541429 @default.
• W4385464226 hasConceptScore W4385464226C2776886416 @default.
• W4385464226 hasConceptScore W4385464226C2778120723 @default.
• W4385464226 hasConceptScore W4385464226C2778336525 @default.
• W4385464226 hasConceptScore W4385464226C71924100 @default.
• W4385464226 hasIssue "3" @default.
• W4385464226 hasLocation W43854642261 @default.
• W4385464226 hasOpenAccess W4385464226 @default.
• W4385464226 hasPrimaryLocation W43854642261 @default.
• W4385464226 hasRelatedWork W1203935567 @default.
• W4385464226 hasRelatedWork W2040331504 @default.
• W4385464226 hasRelatedWork W2145305179 @default.
• W4385464226 hasRelatedWork W2340101648 @default.
• W4385464226 hasRelatedWork W2345090510 @default.
• W4385464226 hasRelatedWork W2412588979 @default.
• W4385464226 hasRelatedWork W2412650345 @default.
• W4385464226 hasRelatedWork W2913672316 @default.
• W4385464226 hasRelatedWork W2947415858 @default.
• W4385464226 hasRelatedWork W2119573293 @default.
• W4385464226 hasVolume "26" @default.
• W4385464226 isParatext "false" @default.
• W4385464226 isRetracted "false" @default.
• W4385464226 workType "article" @default.